Mirum Pharmaceuticals, Inc. MIRM Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $159.88M+43.3% | $148.93M+49.8% | $133.01M+47.2% | $127.79M+64.1% | $111.59M+61.2% | ||
| $97.91M+139% | $51.11M+16.1% | $42.96M+35.5% | $46.07M+41.0% | $41.04M+27.4% | ||
| $96.33M+66.9% | $74.13M+30.4% | $61.91M+22.5% | $63.29M+28.6% | $57.71M+26.4% | ||
| $949.35M+649% | $153.5M+24.2% | $130.41M+26.5% | $132.77M+30.0% | $126.77M+32.5% | ||
| $949.35M+649% | $153.5M+24.2% | $130.41M+26.5% | $132.77M+30.0% | $126.77M+32.5% | ||
| -$789.47M-5,100% | -$4.57M+81.1% | $2.6M+121% | -$4.99M+79.4% | -$15.18M+42.6% | ||
| -493.8%-480pp | -3.1%+21.3pp | 2%+16.0pp | -3.9%+27.2pp | -13.6%+24.6pp | ||
| $3.62M+0.6% | $3.6M+0.5% | $3.61M+0.6% | $3.59M+0.6% | $3.6M+0.5% | ||
| $3.4M+12.5% | $3.42M+6.7% | $3.25M-6.3% | $3.03M-13.0% | $3.02M-16.8% | ||
| $0-100% | $0-100% | $395K+136% | $86K-72.4% | $2.11M+20.0% | ||
| -$789.68M-5,686% | -$4.96M+79.6% | $2.64M+119% | -$5.46M+77.3% | -$13.65M+44.6% | ||
| $475K-53.8% | $767K— | -$262K-176% | $402K-36.7% | $1.03M+64.9% | ||
| -$790.16M-5,284% | -$5.73M+75.9% | $2.91M+120% | -$5.86M+76.2% | -$14.68M+41.9% | ||
| -494.2%-481pp | -3.8%+20.1pp | 2.2%+17.9pp | -4.6%+27.1pp | -13.2%+23.4pp | ||
| -$13.43-4,377% | -$0.12+75.5% | $0.05+117% | -$0.12+76.9% | -$0.30+44.4% | ||
| -$13.43-4,377% | -$0.12+75.5% | $0.06+120% | -$0.12+76.9% | -$0.30+44.4% | ||
| 58.9M+20.4% | 50.2M+5.6% | 57M+19.3% | 49.7M+5.3% | 48.9M+4.2% | ||
| 58.9M+20.4% | 50.2M+5.6% | 50.6M+6.0% | 49.7M+5.3% | 48.9M+4.2% | ||
| $28.81M+25.1% | $28.26M+24.1% | $25.54M+22.7% | $23.42M+15.8% | $23.02M+29.1% | ||
| $726.3M+14,426% | —— | —— | —— | $5M— | ||
| $0-100% | $0-100% | $395K+136% | $86K-72.4% | $2.11M+20.0% | ||
| $97.91M+139% | $51.11M+16.1% | $42.96M+35.5% | $46.07M+41.0% | $41.04M+27.4% | ||
| $159.88M+43.3% | $148.93M+49.8% | $133.01M+47.2% | $127.79M+64.1% | $111.59M+61.2% | ||
| -$789.47M-5,100% | -$4.57M+81.1% | $2.6M+121% | -$4.99M+79.4% | -$15.18M+42.6% | ||
| -$782.59M-8,471% | $1.51M+108% | $8.67M+231% | $1.07M+106% | -$9.13M+56.1% | ||
| -$782.59M-8,471% | $1.51M+108% | $8.67M+231% | $1.07M+106% | -$9.13M+56.1% | ||
| -489.5%-481pp | 1%+19.3pp | 6.5%+13.8pp | 0.8%+24.4pp | -8.2%+21.9pp | ||
| -$789.47M-5,100% | -$4.57M+81.1% | $2.6M+121% | -$4.99M+79.4% | -$15.18M+42.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s revenue?
- Mirum Pharmaceuticals, Inc. (MIRM) generated $569.6M in revenue over the trailing twelve months, up 50.2% year over year.
- Is Mirum Pharmaceuticals, Inc. profitable?
- Mirum Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $798.8M over the trailing twelve months, a -140.2% net margin.
- What is Mirum Pharmaceuticals, Inc.'s earnings per share?
- Mirum Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-13.62.
- Where does Mirum Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
